“Towards access of at least 1 million sequenced Genomes in the EU by 2022”
On April 2018, thirteen member state countries (Czech Republic, Cyprus, Estonia, Finland, Italy, Lithuania, Luxembourg, Malta, Portugal, Slovenia, Spain, Sweden, United Kingdom) signed a declaration on linking genomic databases across borders. Six additional countries (Austria, Bulgaria, Croatia, Greece, Latvia, Netherlands) joined the effort on December 2018, while nine further observer states (Belgium, Denmark, France, Germany, Hungary, Ireland, Norway, Poland, Switzerland) have shown interest in the project. The initiative is aimed at having over 1 million human genomes with phenotypic and clinical data searchable and, under proper conditions, accessible in the EU Member States by 2022, through a federated secure and privacy-respecting environment, in order to provide sufficient scale for new, clinically impactful research and therapeutic and preventive health care.
This cooperation is crucial for enabling research and innovation as well as their efficient translation into clinical settings and public health work, advancing in the understanding of genetic associations that cause or predispose diseases, and facilitating the development of targeted healthcare. In addition, for citizens in the Union, this project will have an impact on early diagnosis and prevention, thus improving health outcomes.
The 1+MG initiative is based on 10 working groups, including scope, stakeholders, governance; ethical, legal and social issues; data standards; good sequencing standards and clinical interpretation; interoperability; health economics; private sector involvement; and three use cases: rare diseases; cancer and common and complex diseases.
Expected benefits from the project for the rare disease community include improved knowledge of the genetic make-up of diseases; advancement in diseases-gene discovery; better understanding of clinical variability and natural history of diseases; anticipation of diagnosis and contribution to solve the unsolved; development of precision medicine tools; prompt dissemination of the most recent expert knowledge; support to the better informed clinicians for making decisions on how to adapt treatment and care pathways; improved health care outcomes and quality of life.
The signatory Member States met on the 5th and 6th of June in Brussels to agree on strategies for managing the 1+MG initiative. A subsequent meeting was arranged on the 28th June by ELIXIR to illustrate the aims, needs and outputs of the project, and the decision was taken to apply for the next WP2020 Coordination and Support action in order to sustain the work of 1+MG.